NCT Number (ID #)	See study LINK below for all details	Trial | Study Synopsis. *See study link for complete details	Contact Information	Some locations are listed below. Note: **There are MANY LOCATIONS for some of these! Including international. CHECK the link study for all locations.	
NCT06374212	https://clinicaltrials.gov/study/NCT06374212	This clinical trial aims to study if a drug called anifrolumab works to treat Hidradenitis Suppurativa (HS) as well as its effect in quality of life before and after treatment. Anifrolumab is a monoclonal antibody that inhibits several processes that have been shown to be involved in the development of HS. The study lasts approximately 40 weeks separated into a screening, treatment, and follow-up phase. Researchers determine if it is safe for the you to receive the drug and if you are eligible for the study during Screening. If eligible for the study, the treatment phase lasts 24 weeks (or six months) with one follow-up visit 12 weeks after the last visit in the treatment phase. During the treatment phase, participants will be asked to come to clinic every two weeks for the first month of treatment, and monthly thereafter for a total of eight treatment visits. Participants will be asked to: * Complete questionnaires asking about the effect of HS in their daily lives and their perception of HS and treatment received. * Receive related medical evaluation * Receive the study drug intravenously * Stay 20 minutes after the infusion for monitoring	Name: Erika Hanami Phone Number: 984-974-3682 Email: erika_hanami@med.unc.edu	UNC Dermatology and Skin Cancer Center, Chapel Hill, North Carolina, 27516, United States	See study link for complete details
NCT05710393	https://clinicaltrials.gov/study/NCT05710393	The aim of this study is to find a genetic link or family trait connecting persons with Hidradenitis Suppurativa (HS) to each other. As a result, discover the cause and perhaps treatment for Hidradenitis Suppurativa (HS).	Name: Frank Brown Jr Phone Number: 773-834-5778 Email: ftbrownjr@uchicagomedicine.org	University of Chicago Medicine, Chicago, Illinois, 60637, United States	See study link for complete details
NCT03967600	https://clinicaltrials.gov/study/NCT03967600	Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.	Name: Hannah Balter Phone Number: 415-502-4741 Email: hannah.balter@ucsf.edu	University of California, San Francisco, San Francisco, California, 94115, United States	See study link for complete details
NCT06058520	https://clinicaltrials.gov/study/NCT06058520	HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There is only one currently FDA-approved treatment, adalimumab, but only 40-60% respond to treatment and over 50% loae response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.	Name: Gretchen Bellefeuille Phone Number: 612-626-0249 Email: belle116@umn.edu	University of Minnesota, Minneapolis, Minnesota, 55414, United States	See study link for complete details
NCT06411379	https://clinicaltrials.gov/study/NCT06411379	This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.	Name: Moonlake Clinical Trial Helpdesk Phone Number: +41 41 510 8022 Email: ClinicalTrials@moonlaketx.com	Clinical Site, Birmingham, Alabama, 35244, United States|Clinical Site, Tampa, Florida, 33613, United States|Clinical Site, Plainfield, Indiana, 46168, United States	See study link for complete details
NCT06411899	https://clinicaltrials.gov/study/NCT06411899	This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.	Name: Moonlake Clinical Trial Helpdesk Phone Number: +41 41 510 8022 Email: ClinicalTrials@moonlaketx.com	Clinical Site, Columbus, Indiana, 47201, United States|Clinical Site, New Albany, Indiana, 47150, United States|Clinical Site, South Jordan, Utah, 84095, United States	See study link for complete details
NCT05403710	https://clinicaltrials.gov/study/NCT05403710	This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.	Contact: Celia Hartigan, RN 774-455-4756 celia.hartigan@umassmed.edu Contact: George Kwapong, MD 774-455-4756 hsresearch@umassmed.edu	University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01605, United States	See study link for complete details
NCT05507125	https://clinicaltrials.gov/study/NCT05507125	The purpose of this protocol is to examine the cytokine profi le of pati ents with hidradeniti s suppurati va (HS) and idemechanisms responsible for post-transcripti onal regulati on of these genes. The primary objecti ve is to determinfollowing cytokines linked to hidradeniti s suppurati va are diff erenti ally expressed in hidradeniti s pati ents versus controlalso doing a sub-study to determine the eff ect of childhood trauma on HS. The parti cipati on in the sub-study is opti onal	"Name: Nabiha Yusuf Phone Number: 2059347432 Email: nabihayusuf@uabmc.edu"	Whitaker Clinic, Birmingham, Alabama, 35294, United States	See study link for complete details
NCT06444087	https://clinicaltrials.gov/study/NCT06444087	The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.	Name: Novartis Pharmaceuticals Phone Number: +41613241111 Email: novartis.email@novartis.com	Novartis Investigative Site, Bordeaux Cedex, 33075, France	See study link for complete details
NCT04218422	https://clinicaltrials.gov/study/NCT04218422	The investigators will investigate battlefield acupuncture as a treatment for the pain of hidradenitis suppurativa.	Dearborn, Michigan, United States, 48124 Recruiting WSUPG Dermatology Contact: Steven D Daveluy 313-429-7854 sdaveluy@med.wayne.edu	WSUPG Dermatology, Dearborn, Michigan, 48124, United States	See study link for complete details
NCT04115566	https://clinicaltrials.gov/study/NCT04115566	Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.	Name: Hannah Balter Phone Number: 415-502-4741 Email: hannah.balter@ucsf.edu	University of California San Francisco, San Francisco, California, 94115, United States	See study link for complete details
NCT06015438	https://clinicaltrials.gov/study/NCT06015438	The purpose of the study is to characterize the challenges to physical activity and exercise for HS patients and design an exercise program (EP) with evidence-based techniques and examine its outcome.	Name: Hadar V Lev-Tov, MD Phone Number: 3052431953 Email: hlevtov@med.miami.edu	University of Miami, Miami, Florida, 33125, United States	See study link for complete details
NCT05020730	https://clinicaltrials.gov/study/NCT05020730	Study PTM-001-01 is a 12-week, randomized, placebo controlled, double blind study with a 12 week open-label extension to examine the immunomodulatory activity of PTM-001 in participants with Hidradenitis Suppurativa (HS). Participants will be randomized to receive PTM-001 (400 mg) or matching placebo every day for 12 weeks after which all participants will receive open-label PTM-001 400 mg daily for an additional 12 weeks. Randomization will be stratified by Hurley Stage.	Name: Ramsey Johnson, MSM Phone Number: 978-726-1478 Email: ramsey@phoenicistx.com	Phoenicis Investigative Site, Redwood City, California, 94063, United States|Phoenicis Investigative Site, Worcester, Massachusetts, 01655, United States|Phoenicis Investigative Site, Cincinnati, Ohio, 45229, United States	See study link for complete details

NCT Number (ID #)	See study LINK below for all details	Trial | Study Synopsis. *See study link for complete details	Contact Information	Some locations are listed below. Note: **There are MANY LOCATIONS for some of these! Including international. CHECK the link study for all locations.	
NCT05635266	https://clinicaltrials.gov/study/NCT05635266	To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.	Name: Carolyn Bidwell Phone Number: 855.836.4759 Email: study@sanguinebio.com	Sanguine Biosciences, Waltham, Massachusetts, 02451, United States	See study link for complete details
NCT06072287	https://clinicaltrials.gov/study/NCT06072287	Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs). Being able to measure whether psychological distress is related to living with a LTC would allow researchers and clinicians to provide interventions specifically tailored to the challenges of living with a LTC and therefore provide the most appropriate support for these patients. Such a measure would also be useful in research to identify the presence of illness-related distress in different patient groups. This project will therefore create a new measure of illness-related distress that has applications for both research and clinical practice. This will involve the psychometric validation of the new illness-related distress measure to test how valid and reliable the measure is. The aim of the project is to provide initial validation of the Illness Related Distress Scale in a community sample, recruited through online platforms. The objective of the study is to gather initial validity and reliability data for the scale.	Name: Natasha Seaton, MSc Phone Number: 0207 188 1189 Email: LTC-study@kcl.ac.uk	King's College London, London, SE1 9RT, United Kingdom	See study link for complete details
NCT05986825	https://clinicaltrials.gov/study/NCT05986825	Validation of the French Version of the Score on Quality of Life in Hidradenitis Suppurativa. The French HiSQOL will be completed by 60 patients with hidradenitis suppurativa a first time, and a second time 1 week later.	Brest, France, 29200 Recruiting CHU Brest Contact: Emilie BRENAUT, PH emilie.brenaut@univ-brest.fr Principal Investigator: Emilie BRENAUT, PH	CHU Brest, Brest, 29200, France	See study link for complete details
NCT05934825	https://clinicaltrials.gov/study/NCT05934825	Multicenter Phase I/II Clinical Trial to Evaluate Safety and Efficiency of Allogenic Adult Mesenchymal Stem Cell from Adipose Tissue in Patients With Hidradenitis Suppurativa	Name: María del Mar Macías Sánchez Phone Number: 671 533 802 Email: mmar.macias@juntadeandalucia.es	Hospital Universitario Virgen de Las Nieves, Granada, 18014, Spain	See study link for complete details
NCT05477225	https://clinicaltrials.gov/study/NCT05477225	This will be a prospective, interventional, single-center, randomized, controlled, comparative study comparing a total of 10 patients treated with BTM and SOC in wounds diagnosed with Hidradenitis suppurativa (5 in each group).	Name: Joan Wilson, MSN, MHA, RN Phone Number: 7063642966 Email: joan.wilson@jmsresearchfoundation.org	Joseph M. Still Research Foundation, Augusta, Georgia, 30909, United States	See study link for complete details
NCT04414514	https://clinicaltrials.gov/study/NCT04414514	Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity. Investigators aim to: * Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment. * Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through translational analyses of skin biopsy samples.	Name: Joslyn Kirby, MD Phone Number: 717-531-1513 Email: jkirby1@pennstatehealth.psu.edu	Penn State Hershey Medical Center, Hershey, Pennsylvania, 17033, United States	See study link for complete details
NCT05989945	https://clinicaltrials.gov/study/NCT05989945	In a prospective observational cohort study (n = 250) the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and HS severity and determine whether these are prognostic markers of heart disease in patients suffering from hidradenitis suppurativa (HS).	Hellerup, Copenhagen, Denmark, 2900 Recruiting Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen Contact: Maria F Dons, MD +4560604780 maria.flarup.dons.01@regionh.dk	Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Copenhagen, 2900, Denmark	See study link for complete details
NCT05642039	https://clinicaltrials.gov/study/NCT05642039	The purpose of this research is to investigate the effectiveness of mindfulness training on the quality of life of Hidradenitis Suppurativa (HS) patients. HS can have a profound impact on quality of life.	Miami, Florida, United States, 33136 Recruiting University of Miami Contact: Hadar Lev-Tov, MD 305-243-8485 hlevtov@med.miami.edu Principal Investigator: Hadar Lev-Tov, MD	University of Miami, Miami, Florida, 33136, United States	See study link for complete details
NCT05997277	https://clinicaltrials.gov/study/NCT05997277	The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study. Dosage of deucravacitinib will be given according to the investigational regimen as follows: 6 mg po bid for 16 weeks. The study compromises a 4-week screening period, a 16-week study period, and a 4-week follow-up period. The follow-up period consists of a follow-up phone call 4 weeks after the last study drug dose.	Boston, Massachusetts, United States, 02215 Recruiting Beth Israel Deaconess Medical Center Contact: Martina Porter, MD 617-667-5834 mporter3@bidmc.harvard.edu Sub-Investigator: Martina Porter, MD	Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States	See study link for complete details
NCT03146676	https://clinicaltrials.gov/study/NCT03146676	This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.	Columbus, Ohio, United States, 43215 Recruiting OSU Dermatology West Contact: Erin Frey 614-366-2025 erin.frey@osumc.edu Contact: Cerah McDaniels-Wilson Cerah.McDanielsWilson@osumc.edu Principal Investigator: Benjamin Kaffenberger, MD	OSU Dermatology West, Columbus, Ohio, 43215, United States	See study link for complete details
NCT05913817	https://clinicaltrials.gov/study/NCT05913817	The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market. The phase IV study is an observational, pan-Canadian, multidisciplinary study aiming to enroll 600 patients across 50-70 sites across 3 different Therapeutic Areas (GI, Rheum, Derm).	Montréal, Quebec, Canada, J4B 5H3 Recruiting JAMP Pharma Corporation Contact: Danny Germain, M.Sc., MBA, RAC, CCPE 438-462-7984 dgermain@jamppharma.com	JAMP Pharma Corporation, Montréal, Quebec, J4B 5H3, Canada	See study link for complete details

NCT Number (ID #)	See study LINK below for all details	Trial | Study Synopsis. *See study link for complete details	Contact Information	Some locations are listed below. Note: **There are MANY LOCATIONS for some of these! Including international. CHECK the link study for all locations.	
NCT06324552	https://clinicaltrials.gov/study/NCT06324552	NOTCH signaling in the skin exerts a pivotal role in the regulation of normal keratinocytes turnover by mediating the balance between proliferation, differentiation, apoptosis and autophagic flux progression. Two skin diseases are characterized by the presence of gene variants that cause an impairment in NOTCH signaling: hidradenitis suppurativa(HS) and Dowling-Degos disease(DDD). To date, both HS and DDD are orphan diseases still lacking of specific treatments. This project aims at improving the current knowledge on the pathogenesis of HS and DDD, by deepening the understandings on the role played by keratinocytes in these pathologies and also by determining why mutations found in the same pathway cause different diseases. This study aimed to obtain in vitro models, derived directly from patients (from hair follicles) and from keratinocytes (HaCaT) cell cultures, for the study of these skin pathologies and also for the testing of novel innovative therapies such as photobiomodulation therapy.	Name: Paola Maura Tricarico, BSc Phone Number: +39 0403785111 Email: paolamaura.tricarico@burlo.trieste.it	Medical Un/iversity Innsbruck, Innsbruck, Austria|Université Libre de Bruxelles, Bruxelles, Belgium|Université Paris Est-Créteil / INSERM U955- Mondor Institute For Biomedical Research (IMRB), Créteil, France|Centre National de la Recherche Scientifique, Strasbourg, France|Dessau Medical Cente, Brandenburg, Germany|Uniklinik Köln, Köln, Germany|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinic, Milano, Italy|Azienda ospedaliero-universitaria pisana, Pisa, Italy|Istituto Dermopatico dell'Immacolata, IRCCS, Roma, Italy|Passion people, Roma, Italy|Policlinico Universitario Fondazione A. Gemelli IRCCS, Roma, Italy|Ospedale Maggiore di Trieste, Trieste, 34125, Italy|Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, 34137, Italy|Ospedale San Bortolo, Vicenza, Italy|Jozef Stefan Institute,	See study link for complete details
NCT06241573	https://clinicaltrials.gov/study/NCT06241573	This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100). The purpose of this study is to find out how well people tolerate spesolimab and whether it helps people with HS in the long-term. For about 1.5 years, participants get spesolimab injections under the skin every 2 weeks. Participants are in the study for about 2 years. During this time, participants have 41 visits. 24 visits are done at the study site. 17 visits can be done by video call at the participant's home. At study visits, doctors check the severity of the participant's HS and collect information on any health problems of the participants.	Name: Boehringer Ingelheim Phone Number: 18002430127 Email: clintriage.rdg@boehringer-ingelheim.com	Holdsworth House Medical Practice, Sydney, New South Wales, 2010, Australia|SimcoDerm Medical and Surgical Dermatology Centre, Barrie, Ontario, L4M 7G1, Canada|Dr. S. K. Siddha Medicine Professional Corporation, Newmarket, Ontario, L3Y 5G8, Canada|The University of Tokyo Hospital, Tokyo, Bunkyo-ku, 113-8655, Japan|National University Hospital, Singapore, 119074, SingaporeMANY LOCATIONS! Including international. CHECK link study for all locations. "MANY LOCATIONS! Including international. CHECK link study for all locations.	See study link for complete details
NCT05066113	https://clinicaltrials.gov/study/NCT05066113	This research is being done to assess the effect of radiofrequency (RF)-based treatment on skin and skin conditions.	Baltimore, Maryland, United States, 21287 Recruiting Johns Hopkins School of Medicine Contact: Ruizhi Wang 410-502-7546 rwang@jhmi.edu Principal Investigator: Noori Kim, MD	Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States	See study link for complete details
NCT06368388	https://clinicaltrials.gov/study/NCT06368388	PHAGEFORCE is a prospective, observational registry study. The University Hospitals Leuven has approved the application of phage therapy as standard-of-care only in patients for whom no curative treatment alternatives (antibiotic and/or surgical) are available ('last-resort cases'). A multidisciplinary phage task force, referred to as the Coordination group for Bacteriophage therapy Leuven (CBL) was set up. The CBL screens patients with difficult-to-treat infections, evaluates who could benefit from phage therapy and sets up the treatment protocol. With this study, the CBL aims to gain insight in the safety and efficacy of phage therapy by integrating and optimizing phage therapy in five distinct medical disciplines (with distinct routes of administration), facilitating long-term follow-up of patients. Furthermore, this study will gain insight in the biodistribution and exact mechanisms of action of phage therapy and thus be able to provide standardized guidelines for each patient population and route of administration.	Name: Jolien Onsea, PhD Phone Number: 00321642041 Email: jolien.onsea@uzleuven.be	University Hospitals Leuven, Leuven, 3000, Belgium	See study link for complete details
NCT05994976	https://clinicaltrials.gov/study/NCT05994976	The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.	Name: Julie Bedoucha, MSc Phone Number: 514-521-4285 ext 253 Email: jbedoucha@innovaderm.com	Innovaderm Research Inc., Montréal, Quebec, H2X 2V1, Canada	See study link for complete details
NCT04246372	https://clinicaltrials.gov/study/NCT04246372	People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions. The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug known to block IFN signaling, in adolescents and adults with DS and an autoimmune and/or autoinflammatory skin condition. Investigators will also measure the impact of interferon inhibition on a variety of molecular markers, as well as the cognitive abilities and quality of life of participants.	Name: Angela Rachubinski, PhD Phone Number: 303-724-7366 Email: DSresearch@cuanschutz.edu	Linda Crnic Institute for Down Syndrome, Aurora, Colorado, 80045, United States	See study link for complete details
NCT04191395	https://clinicaltrials.gov/study/NCT04191395	Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points.	Besançon, France, 25000 Recruiting Charline Vauchy Contact: Charline Vauchy, PhD cvauchy@chu-besancon.fr Principal Investigator: Clément Prati, Prof.Show more	Charline Vauchy, Besançon, 25000, France	See study link for complete details
NCT06361836	https://clinicaltrials.gov/study/NCT06361836	This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.	Boston, Massachusetts, United States, 02115 Recruiting Brigham and Women's Hospital Contact: Oliva Gabriel 617-525-8250 ogabriel@bwh.harvard.edu	Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|SLUCare Academic Pavillion, Saint Louis, Missouri, 63110, United States	See study link for complete details
NCT05243966	https://clinicaltrials.gov/study/NCT05243966	This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.	Name: Barnaby May, PhD Phone Number: +64 21 056 9995 Email: barnaby.may@aroabio.com	Surgery Group LA, Los Angeles, California, 90048, United States|Associates in Medicine & Surgery, Fort Myers, Florida, 33919, United States|Northeast Georgia Medical Center, Inc., Gainesville, Georgia, 30501, United States|University Medical Center, New Orleans, Louisiana, 70112, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, 70115, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States|Nuvance Health Vassar Brothers Medical Center, Poughkeepsie, New York, 12601, United States|Moses H Cone Memorial Hospital Operating Corporation, Greensboro, North Carolina, 27401-1004, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, United States|Tower Health Reading Hospital, West Reading, Pennsylvania, 19611, United States	See study link for complete details
NCT06468228	https://clinicaltrials.gov/study/NCT06468228	Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with moderate to severe HS. Visit site to see more	Name: ABBVIE CALL CENTER Phone Number: 844-663-3742 Email: abbvieclinicaltrials@abbvie.com	Cahaba Dermatology & Skin Health Center /ID# 263795, Birmingham, Alabama, 35244, United States|Medical Dermatology Specialists /ID# 263394, Phoenix, Arizona, 85006, United States|Joseph Raoof Md,Inc /Id# 263756, Encino, California, 91436, United States|Integrative Skin Science and Research /ID# 264600, Sacramento, California, 95815, United States|Dermatology Partners of Leawood /ID# 263533, Leawood, Kansas, 66211, United States|Dermatology and Skin Center of Lees Summit /ID# 263567, Lee's Summit, Missouri, 64064-2301, United States|Center for Clinical Studies - Houston - Binz Street /ID# 263378, Houston, Texas, 77004, United States|Virginia Clinical Research, Inc. /ID# 264553, Norfolk, Virginia, 23502	See study link for complete details

NCT Number (ID #)	See study LINK below for all details	Trial | Study Synopsis. *See study link for complete details	Contact Information	Some locations are listed below. Note: **There are MANY LOCATIONS for some of these! Including international. CHECK the link study for all locations.	
NCT04508374	https://clinicaltrials.gov/study/NCT04508374	Hidradenitis suppurativa (HS) is a common chronic skin disease where patients experience inflamed painful nodules and chronic suppurating tunnels under the skin that often leave mutilating scars. Symptoms typically begin during adolescence and patients struggle with pain, pruritus, malodor and purulent discharge compromising work life, physical exercise, and sexual habits. Consequently, the risk of social exclusion, anxiety, depression, and suicide is increased among patients suffering from HS.	Name: Gregor BE Jemec, Prof., DmSc Phone Number: +4547322600 Email: gbj@regionsjaelland.dk	zealand University Hospital Roskilde, Roskilde, 4000, Denmark	See study link for complete details
NCT06046729	https://clinicaltrials.gov/study/NCT06046729	This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.	Phoenix, Arizona, United States, 85006 Recruiting Medical Dermatology Specialists Contact: 602-354-5770 Principal Investigator: Lindsay Ackerman	Medical Dermatology Specialists, Phoenix, Arizona, 85006, United States|Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona, 85008, United States|Arkansas Research Trials, LLC, North Little Rock, Arkansas, 72117, United States|Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, 72758, United States|First OC Dermatology Research Inc, Fountain Valley, California, 92708, United States|Center for Dermatology Clinical Research, Inc., Fremont, California, 94538, United States|Dermatology Research Associates, Los Angeles, California, 90045, United States|Dermatology Institute and Skin Care Center, Santa Monica, California, 90404, United States|University of Connecticut, Farmington, Connecticut, 06032, United States|Direct Helpers Research Center, Hialeah, Florida, 33012, United States|University of Miami, Miami, Florida, 33125, United States|Skin Research of South Florida, Miami, Florida, 33173-1407, United States|ForCare Clinical Research, Tampa, Florida, 33613-1244, United States|Alliance Clinical Research of Tampa Loc. 1, Tampa, Florida, 33615, United States|Olympian Clinical Research, Tampa, Florida, 33615, United States|Advanced Medical Research, PC, Sandy Springs, Georgia, 30328, United States|NorthShore Medical Group Dermatology - Skokie, Skokie, Illinois, 60077-1049, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, 46250, United States|Derm Research LLC, Louisville, Kentucky, 40217, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Revival Research Institute - Troy, Troy, Michigan, 48084	See study link for complete details
NCT05139602	https://clinicaltrials.gov/study/NCT05139602	Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy.	Name: ABBVIE CALL CENTER Phone Number: 844-663-3742 Email: abbvieclinicaltrials@abbvie.com	Medical Dermatology Specialists /ID# 240641, Phoenix, Arizona, 85006, United States|Mayo Clinic - Scottsdale /ID# 241030, Scottsdale, Arizona, 85259-5452, United States|Burke Pharmaceutical Research /ID# 240811, Hot Springs, Arkansas, 71913-6404, United States|UCSF Fresno /ID# 240903, Fresno, California, 93701-2302, United States|Medderm Associates /ID# 240729, San Diego, California, 92103, United States|Clinical Trials Research Institute /ID# 240642, Thousand Oaks, California, 91320-2130, United States|CCD Research, PLLC /ID# 240728, Cromwell, Connecticut, 06416-1745, United States|Skin Care Research - Boca Raton /ID# 240758, Boca Raton, Florida, 33486-2269, United States|Apex Clinical Trials /ID# 248558, Brandon, Florida, 33511, United States|GSI Clinical Research, LLC /ID# 240901, Margate, Florida, 33063, United States|Florida International Rsrch cr /ID# 240902, Miami, Florida, 33173, United States|Park Avenue Dermatology, PA /ID# 240807, Orange Park, Florida, 32073, United States|TruDerm Dermatology of Wellington /ID# 240780, Wellington, Florida, 33449	See study link for complete details
NCT05921994	https://clinicaltrials.gov/study/NCT05921994	The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.	Name: Novartis Pharmaceuticals Phone Number: +41613241111 Email: novartis.email@novartis.com	Novartis Investigative Site, Aachen, 52064, Germany|Novartis Investigative Site, Ahaus, 48683, Germany|Novartis Investigative Site, Annaberg-Buchholz, 09456, Germany|Novartis Investigative Site, Bergen, 18528, Germany|Novartis Investigative Site, Berlin, 12159, Germany|Novartis Investigative Site, Berlin, 13086, Germany|Novartis Investigative Site, Berlin, 13507, Germany|Novartis Investigative Site, Berlin, 13595, Germany|Novartis Investigative Site, Berlin, 14052, Germany|Novartis Investigative Site, Bielefeld, 33647, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Bonn, 53105,	See study link for complete details
NCT05620823	https://clinicaltrials.gov/study/NCT05620823	The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.	Name: Incyte Corporation Call Center (US) Phone Number: 1.855.463.3463 Email: medinfo@incyte.com	Investigative Site US303, Phoenix, Arizona, 85006, United States|Investigative Site US307, Fort Smith, Arkansas, 72916, United States|Investigative Site US315, Laguna Niguel, California, 92677, United States|Investigative Site US326, Los Angeles, California, 90045, United States|Investigative Site US323, San Francisco, California, 94118, United States|Investigative Site US306, Boca Raton, Florida, 33486, United States|Investigative Site US320, Boca Raton, Florida, 33486, United States|Investigative Site US317, Hialeah, Florida, 33012-3618, United States|Investigative Site US321, North Miami Beach, Florida, 33162-4708, United States|Investigative Site US316, Orlando, Florida, 32819, United States|Investigative Site US328, Tampa, Florida, 33612, United States|Investigative Site US311, Marietta, Georgia, 30060-1047, United States|Investigative Site US327, Chicago, Illinois, 60612, United States|Investigative Site US319, Skokie, Illinois, 60077, United States|Investigative Site US332, Iowa City, Iowa, 52242, United States|Investigative Site US325, Columbia, Maryland, 21045, United States|Investigative Site US318, Beverly, Massachusetts, 01915, United States|Investigative Site US304, Boston, Massachusetts, 02215, United States|Investigative Site US310, Brighton, Massachusetts, 02135, United States|Investigative Site US302, Saint Louis, Missouri, 63110, United States|Investigative Site US331, Albuquerque, New Mexico, 87102, United States|Investigative Site US324, Kew Gardens, New York, 11415, United States|Investigative Site US330, Boardman, Ohio, 44512, United States|Investigative Site US314, Cincinnati, Ohio, 45219	See study link for complete details

NCT Number (ID #)	See study LINK below for all details	Trial | Study Synopsis. *See study link for complete details	Contact Information	Some locations are listed below. Note: **There are MANY LOCATIONS for some of these! Including international. CHECK the link study for all locations.	
NCT05620836	https://clinicaltrials.gov/study/NCT05620836	The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.	Name: Incyte Corporation Call Center (US) Phone Number: 1.855.463.3463 Email: medinfo@incyte.com	Investigative Site US240, Scottsdale, Arizona, 85255, United States|Investigative Site US237, Scottsdale, Arizona, 85259, United States|Investigative Site US214, Arkansas, Arkansas, 72758, United States|Investigative Site US242, Fayetteville, Arkansas, 72703, United States|Investigative Site US223, Los Angeles, California, 90033, United States|Investigative Site US226, San Diego, California, 92103, United States|Investigative Site US222, San Francisco, California, 94118, United States|Investigative Site US233, Washington, District of Columbia, 20060, United States|Investigative Site US228, Brandon, Florida, 33511, United States|Investigative Site US227, Margate, Florida, 33063, United States|Investigative Site US204, Miami, Florida, 33125, United States|Investigative Site US236, Miami, Florida, 33173, United States|Investigative Site US200, Ocala, Florida, 34470, United States|Investigative Site US201, Tampa, Florida, 33613, United States|Investigative Site US220, West Dundee, Illinois, 60118, United States|Investigative Site US206, Indianapolis, Indiana, 46250, United States|Investigative Site US241, Iowa City, Iowa, 52242, United States|Investigative Site US209, Louisville, Kentucky, 40241, United States|Investigative Site US207, Metairie, Louisiana, 70006, United States|Investigative Site US229, New Orleans, Louisiana, 70115, United States|Investigative Site US224, Baltimore, Maryland, 21224, United States|Investigative Site US208, Beverly, Massachusetts, 01915, United States|Investigative Site US221	See study link for complete details
NCT05819398	https://clinicaltrials.gov/study/NCT05819398	This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS. People who have previously taken specific medicines such as immunosuppressive biologics other than Tumor necrosis factor (TNF) inhibitors cannot take part.	Name: Boehringer Ingelheim Phone Number: 1-800-243-0127 Email: clintriage.rdg@boehringer-ingelheim.com	First OC Dermatology, Fountain Valley, California, 92708, United States|Dermatology Research Associates, Los Angeles, California, 90045, United States|Integrative Skin Science and Research, Sacramento, California, 95815, United States|Clinical Trials Research Institute, Thousand Oaks, California, 91320, United States|Ziaderm Research, North Miami Beach, Florida, 33162, United States|ForCare Clinical Research, Inc., Tampa, Florida, 33613, United States|Olympian Clinical Research, Tampa, Florida, 33615, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, 46250, United States|Skin Sciences, PLLC, Louisville, Kentucky, 40217, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Oakland Hills Dermatology, PC, Auburn Hills, Michigan, 48326, United States|Skin Specialists, P.C., Omaha, Nebraska, 68144, United States|AXIS Clinicals, Fargo, North Dakota, 58103, United States|Unity Clinical Research, Oklahoma City, Oklahoma, 73118, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Palmetto Clinical	See study link for complete details
NCT06212999	https://clinicaltrials.gov/study/NCT06212999	The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \ [NCT05620836\]).	Name: Incyte Corporation Call Center (US) Phone Number: 1.855.463.3463 Email: medinfo@incyte.com	Investigative Site US303, Phoenix, Arizona, 85006, United States|Investigative Site US307, Fort Smith, Arkansas, 72916, United States|Investigative Site US214, Rogers, Arkansas, 72758, United States|Investigative Site US315, Laguna Niguel, California, 92677, United States|Investigative Site US223, Los Angeles, California, 90089, United States|Investigative Site US226, San Diego, California, 92103, United States|Investigative Site US222, San Francisco, California, 94118, United States|Investigative Site US233, Washington, District of Columbia, 20060, United States|Investigative Site US228, Brandon, Florida, 33511, United States|Investigative Site US309, Clearwater, Florida, 33614, United States|Investigative Site US317, Hialeah, Florida, 33012-3618, United States|Investigative Site US306, Hollywood, Florida, 33021, United States|Investigative Site US320, Hollywood, Florida, 33021, United States|Investigative Site US316, Maitland, Florida, 32751, United States|Investigative Site US227, Margate, Florida, 33063, United States|Investigative Site US204, Miami, Florida, 33136, United States|Investigative Site US321, North Miami Beach, Florida, 33162, United States|Investigative Site US200, Ocala, Florida, 34470, United States|Investigative Site US201, Tampa, Florida, 33613, United States|Investigative Site US311, Marietta, Georgia, 30060, United States|Investigative Site US319, Skokie, Illinois, 60077, United States|Investigative Site US220, West Dundee, Illinois, 60118, United States|Investigative Site US206	See study link for complete details
NCT06028230	https://clinicaltrials.gov/study/NCT06028230	This is a parallel, Phase 2, 2-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years. Study details include: * Screening period: up to 4 weeks (30 days) * Treatment duration: up to 16 weeks * Follow-up period: up to 4 weeks * Total study duration: up to 24 weeks * Number of visits: 14	Name: Trial Transparency email recommended (Toll free number for US & Canada) Phone Number: 8006331610 ext option 6 Email: contact-us@sanofi.com	Clear Dermatology & Aesthetics Center Scottsdale Site Number : 8400006, Scottsdale, Arizona, 85255-4140, United States|First OC Dermatology Site Number: 8400007, Fountain Valley, California, 92708-3701, United States|Encore Medical Research - Boyton Beach Site Number : 8400002, Boynton Beach, Florida, 33436-7245, United States|TrueBlue Clinical Research - Brandon - HyperCore - PPDS Site Number : 8400001, Brandon, Florida, 33511-4850, United States|Encore Medical Research Site Number : 8400005, Hollywood, Florida, 33021-6467, United States|Tory Sullivan, MD, PA Site Number: 8400003, North Miami Beach, Florida, 33162-4708, United States|Encore Medical Research Site Number: 8400010, Weston, Florida, 33331-3643, United States|Dermatology Specialists Research - 3810 Springhurst Blvd	See study link for complete details
NCT06118099	https://clinicaltrials.gov/study/NCT06118099	This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (HS).	Name: Trial Transparency email recommended (Toll free for US & Canada) Phone Number: 800-633-1610 ext option 6 Email: contact-us@sanofi.com	Medical Dermatology Specialists Site Number : 8400002, Phoenix, Arizona, 85006-2722, United States|Center for Dermatology Clinical Research Site Number : 8400010, Fremont, California, 94538-1601, United States|Corazon USA, LLC (DBA Life Clinical Trials) Site Number : 8400011, Margate, Florida, 33063, United States|Washington University School of Medicine Site Number : 8400007, Saint Louis, Missouri, 63110, United States|Centricity Research Site Number : 8400009, Dublin, Ohio, 43016, United States|Clinical Partners, LLC Site Number : 8400003, Johnston, Rhode Island, 02919, United States|Center for Clinical Studies, LTD. LLP Site Number : 8400001, Houston, Texas, 77004, United States|Investigational Site Number : 0360003, Phillip, Australian Capital Territory, 2606, Australia|Investigational Site Number : 0360001, Darlinghurst, New South Wales, 2010, Australia|Investigational Site Number : 0360002, Melbourne, Victoria,	See study link for complete details

NCT Number (ID #)	See study LINK below for all details	Trial | Study Synopsis. *See study link for complete details	Contact Information	Some locations are listed below. Note: **There are MANY LOCATIONS for some of these! Including international. CHECK the link study for all locations.	
NCT03661866	https://clinicaltrials.gov/study/NCT03661866	TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.	Name: Laura Dalfonso Phone Number: 9842340268 Email: ldalfonso@targetrwe.com	Clear Dermatology & Aesthetics Center/Investigative MD, Scottsdale, Arizona, 85255, United States|Johnson Dermatology, Fort Smith, Arkansas, 72916, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Arkansas Dermatology, Little Rock, Arkansas, 72223, United States|First OC Dermatology, Fountain Valley, California, 92708, United States|Center for Dermatology Cosmetic and Laser Surgery, Fremont, California, 94538, United States|University of California, Irvine, California, 92697, United States|University of California - San Diego/Rady Children's Hospital, San Diego, California, 92123, United States|George Washington University, Washington, District of Columbia, 20037, United States|Feinstein Dermatology and Cosmetic Surgery, Hollywood, Florida, 33021, United States|Academic Alliance in Dermatology, Tampa, Florida, 33614, United States|Integrated Dermatology of West Palm Beach, West Palm Beach, Florida, 33406, United States|Lurie Children's Hospital/Northwestern University, Chicago, Illinois, 60611, United States|Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group, Indianapolis, Indiana, 46520, United States|The University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Family Allergy and Asthma Research Institute, Louisville, Kentucky, 40215, United States|DermAssociates, LCC, Rockville, Maryland, 20850, United States|Integrated Dermatology of Massachusetts, Quincy, Massachusetts, 02169, United States|University of Massachusetts Medical School, Worcester, Massachusetts	See study link for complete details
NCT03827798	https://clinicaltrials.gov/study/NCT03827798	The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.	Name: Novartis Pharmaceuticals Phone Number: 1-888-669-6682 Email: novartis.email@novartis.com	Olympian Clinical Research ., Clearwater, Florida, 33756, United States|Park Avenue Dermatology, PA, Orange Park, Florida, 32073, United States|Olympian Clinical Research ., Tampa, Florida, 33609, United States|University of South Florida, Tampa, Florida, 33612, United States|Advanced Medical Research, Sandy Springs, Georgia, 30328, United States|NorthShore University Health System North Shore, Skokie, Illinois, 60077, United States|Dawes Fretzin Clinical Rea Group, Indianapolis, Indiana, 46250, United States|Beth Israel Deaconess Medical Cente, Boston, Massachusetts, 02215, United States|Skin Specialists PC ., Omaha, Nebraska, 68144, United States|Penn State Milton S Hershey Medical Center ., Hershey, Pennsylvania, 17033-0850, United States|Medical University of South Carolina MUSC ., Charleston, South Carolina, 29425, United States|Novartis Investigative Site, Graz, 8036, Austria|Novartis Investigative Site, Wien, A 1090, Austria|Novartis Investigative Site, Bruxelles, 1070, Belgium|Novartis Investigative Site, Prague, Prague 1, 11000, Czechia|Novartis Investigative Site, Copenhagen NV, 2400, Denmark|Novartis Investigative Site.	See study link for complete details